- Home
- GLUE vs SES Comparison
GLUE vs SES Comparison
Compare GLUE & SES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- SES
- Stock Information
- Founded
- GLUE 2019
- SES 2012
- Country
- GLUE United States
- SES United States
- Employees
- GLUE N/A
- SES N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- SES Auto Parts:O.E.M.
- Sector
- GLUE Health Care
- SES Consumer Discretionary
- Exchange
- GLUE Nasdaq
- SES Nasdaq
- Market Cap
- GLUE 351.2M
- SES 384.0M
- IPO Year
- GLUE 2021
- SES N/A
- Fundamental
- Price
- GLUE $4.82
- SES $1.12
- Analyst Decision
- GLUE Buy
- SES Hold
- Analyst Count
- GLUE 2
- SES 3
- Target Price
- GLUE $13.50
- SES $1.50
- AVG Volume (30 Days)
- GLUE 423.8K
- SES 7.7M
- Earning Date
- GLUE 08-07-2025
- SES 08-04-2025
- Dividend Yield
- GLUE N/A
- SES N/A
- EPS Growth
- GLUE N/A
- SES N/A
- EPS
- GLUE 0.29
- SES N/A
- Revenue
- GLUE $177,986,000.00
- SES $11,360,000.00
- Revenue This Year
- GLUE $49.02
- SES $916.42
- Revenue Next Year
- GLUE N/A
- SES $151.67
- P/E Ratio
- GLUE $16.38
- SES N/A
- Revenue Growth
- GLUE 2990.57
- SES N/A
- 52 Week Low
- GLUE $3.50
- SES $0.20
- 52 Week High
- GLUE $12.40
- SES $2.53
- Technical
- Relative Strength Index (RSI)
- GLUE 51.76
- SES 51.45
- Support Level
- GLUE $4.30
- SES $1.02
- Resistance Level
- GLUE $4.70
- SES $1.16
- Average True Range (ATR)
- GLUE 0.25
- SES 0.08
- MACD
- GLUE 0.02
- SES -0.01
- Stochastic Oscillator
- GLUE 85.89
- SES 50.98
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.